doxorubicin hydrochloride has been researched along with camptothecin in 33 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (6.06) | 29.6817 |
2010's | 30 (90.91) | 24.3611 |
2020's | 1 (3.03) | 2.80 |
Authors | Studies |
---|---|
Choo, HY; Jung, MJ; Kim, MH; Kwon, Y; Lim, SY; Rhee, HK | 1 |
Cho, HJ; Jung, MJ; Kwon, Y; Na, Y | 1 |
Jahng, Y; Jung, MJ; Karki, R; Kwon, Y; Lee, ES; Na, Y; Nam, JM; Thapa, P; Thapa, U | 1 |
Basnet, A; Cho, WJ; Choi, H; Choi, JH; Jahng, Y; Jeong, BS; Karki, R; Kwon, Y; Lee, CS; Lee, ES; Na, Y; Thapa, P; Yun, M | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Cho, HJ; Jung, MJ; Kim, J; Kwon, Y; Lee, ES; Na, Y; Woo, S | 1 |
Cho, WJ; Choi, H; Choi, JH; Jeong, BS; Jung, MJ; Karki, R; Kwon, Y; Lee, ES; Na, Y; Nam, JM; Thapa, P; Yun, M | 1 |
Cho, WJ; Jeong, TC; Kang, MJ; Karki, R; Kim, HL; Kwon, Y; Lee, ES; Na, Y; Nam, JM; Thapa, P | 1 |
Ha, EM; Kang, DH; Kwon, Y; Lee, CS; Lee, ES; Na, Y; Nam, JM; Woo, S | 1 |
Jun, KY; Jung, MJ; Kwon, Y; Lee, ES; Lee, EY; Lee, OH; Na, Y; Park Choo, HY | 1 |
Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
Bhushan, S; Murthy, YL; Nagendra Sastry, Y; Pathania, AS; Suhasini, KP | 1 |
Jee, JG; Jun, KY; Kadayat, TM; Karki, R; Kwon, Y; Lee, ES; Lee, JH; Park, C; Thapa, P | 1 |
Chen, W; Li, Z; Lu, C; Shen, Y; Zhang, M | 1 |
Arora, R; Arora, S; Chashoo, G; Chaudhry, A; Ishar, MP; Saxena, AK; Sharma, V | 1 |
Bist, G; Kadayat, TM; Kwon, Y; Lee, ES; Magar, TB; Na, Y; Shin, S; Shrestha, A; Song, C; Thapa, P | 1 |
Bist, G; Jun, KY; Kadayat, TM; Kwon, Y; Lee, ES; Magar, TB; Na, Y; Park, S; Shrestha, A | 1 |
Bist, G; Jun, KY; Kadayat, TM; Karki, R; Kwon, Y; Lee, ES; Na, Y; Shin, S; Shrestha, A; Thapa Magar, TB | 1 |
Abdel-Aziz, HA; Ahmad, P; Jun, KY; Kadi, AA; Kwon, Y; Rahman, AF; Woo, H | 1 |
Hong, E; Jun, KY; Kwak, SY; Kwon, Y; Lee, ES; Na, Y; Park, S | 1 |
Bist, G; Jun, KY; Kadayat, TM; Kwon, Y; Lee, ES; Park, S; Shrestha, A; Thapa Magar, TB | 1 |
Islam, MS; Kadi, AA; Kwon, Y; Park, S; Rahman, AF; Song, C | 1 |
Jeon, KH; Kwak, SY; Kwon, Y; Na, Y; Yu, HB | 1 |
Bist, G; Kadayat, TM; Kwon, Y; Lee, ES; Lee, HJ; Park, S; Shrestha, A; Thapa Magar, TB | 2 |
Ding, J; Han, G; Liu, Y; Meng, C; Meng, LH; Qing, L; Shi, J; Wang, Q; Wang, Y; Wang, Z; Yang, Y | 1 |
Bist, G; Kwon, Y; Lee, ES; Park, S; Shrestha, A; Song, C; Thapa Magar, TB | 1 |
Cho, WJ; Han, J; Jin, Y; Khadka, DB; Kwon, Y; Park, S | 1 |
Jo, H; Kwon, Y; Lee, ES; Shrestha, A | 1 |
Bist, G; Jo, H; Kadayat, TM; Katila, P; Kwon, Y; Lee, ES; Magar, TBT; Seo, SH; Shrestha, A | 1 |
Jang, HJ; Katila, P; Kwon, Y; Lee, ES; Park, S; Shrestha, A; Shrestha, R | 1 |
Hwang, SY; Jeon, YH; Jeong, TC; Jo, H; Kadayat, TM; Katila, P; Kim, KS; Kim, SK; Koh, WS; Kwon, Y; Lee, ES; Nepal, MR; Noh, K; Park, S; Shrestha, A; Shrestha, R | 1 |
Bist, G; Hwang, SY; Jang, H; Jeon, KH; Kadayat, TM; Kim, S; Kunwar, S; Kwon, Y; Lee, ES; Park, S; Seo, M; Sheen, N; Shrestha, A | 1 |
33 other study(ies) available for doxorubicin hydrochloride and camptothecin
Article | Year |
---|---|
Synthesis of isoquinolinone-based tetracycles as poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; DNA Damage; Enzyme Inhibitors; Heterocyclic Compounds, 4 or More Rings; Humans; Isoquinolines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinolones | 2009 |
Oxiranylmethyloxy or thiiranylmethyloxy-azaxanthones and -acridone analogues as potential topoisomerase I inhibitors.
Topics: Acridines; Antineoplastic Agents; Aza Compounds; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Molecular Structure; Stereoisomerism; Structure-Activity Relationship; Topoisomerase I Inhibitors; Xanthones | 2009 |
2-Thienyl-4-furyl-6-aryl pyridine derivatives: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Neoplasms; Pyrimidines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2010 |
2,6-Dithienyl-4-furyl pyridines: Synthesis, topoisomerase I and II inhibition, cytotoxicity, structure-activity relationship, and docking study.
Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Computer Simulation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; Pyridines; Structure-Activity Relationship; Thiophenes; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
New benzoxanthone derivatives as topoisomerase inhibitors and DNA cross-linkers.
Topics: Antineoplastic Agents; Benzene Derivatives; Cell Line, Tumor; Cell Proliferation; DNA; DNA Topoisomerases; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Xanthones | 2010 |
Synthesis of 2-(thienyl-2-yl or -3-yl)-4-furyl-6-aryl pyridine derivatives and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
Topics: Antineoplastic Agents; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Molecular Structure; Pyridines; Stereoisomerism; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2010 |
Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl pyridines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytotoxins; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Molecular Structure; Pyridines; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2010 |
Synthesis and pharmacological evaluation of new methyloxiranylmethoxyxanthone analogues.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cross-Linking Reagents; DNA; DNA Topoisomerases, Type II; Humans; Topoisomerase II Inhibitors; Xanthones | 2010 |
Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Biocatalysis; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HeLa Cells; HL-60 Cells; Humans; Models, Molecular; Molecular Structure; Stereoisomerism; Structure-Activity Relationship; Topoisomerase II Inhibitors; Xanthones | 2011 |
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
Synthesis, structure activity relationship and mode of action of 3-substitutedphenyl-1-(2,2,8,8-tetramethyl-3,4,9,10-tetrahydro-2H,8H-pyrano[2,3-f]chromen-6-yl)-propenones as novel anticancer agents in human leukaemia HL-60 cells.
Topics: Antineoplastic Agents; Benzopyrans; Caco-2 Cells; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chalcones; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; MCF-7 Cells; Molecular Structure; Structure-Activity Relationship | 2013 |
Synthesis, antitumor activity, and structure-activity relationship study of trihydroxylated 2,4,6-triphenyl pyridines as potent and selective topoisomerase II inhibitors.
Topics: Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HEK293 Cells; Humans; Molecular Docking Simulation; Molecular Structure; Neoplasms; Phenols; Pyridines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2014 |
Design and synthesis of 2-phenylnaphthalenoids as inhibitors of DNA topoisomeraseIIα and antitumor agents.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Mice; Mice, Nude; Molecular Structure; Naphthalenes; Neoplasms, Experimental; Quantitative Structure-Activity Relationship; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2014 |
β-Ionone derived apoptosis inducing endoperoxides; Discovery of potent leads for anticancer agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Survival; CHO Cells; Cricetinae; Cricetulus; DNA; Drug Design; Humans; Intracellular Space; L-Lactate Dehydrogenase; Membrane Potential, Mitochondrial; Norisoprenoids; Peroxides; Reactive Oxygen Species | 2014 |
Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of 2-phenyl- or hydroxylated 2-phenyl-4-aryl-5H-indeno[1,2-b]pyridines.
Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; Hydroxylation; Inhibitory Concentration 50; Molecular Structure; Protein Binding; Pyridines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2015 |
Effect of chlorine substituent on cytotoxic activities: Design and synthesis of systematically modified 2,4-diphenyl-5H-indeno[1,2-b]pyridines.
Topics: Antineoplastic Agents; Biphenyl Compounds; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Design; Female; Halogenation; HeLa Cells; Humans; Indenes; Pyridines; Structure-Activity Relationship; Topoisomerase Inhibitors | 2016 |
A new series of 2-phenol-4-aryl-6-chlorophenyl pyridine derivatives as dual topoisomerase I/II inhibitors: Synthesis, biological evaluation and 3D-QSAR study.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Pyridines; Quantitative Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2016 |
Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
Topics: Adenosine Triphosphate; Antigens, Neoplasm; Antineoplastic Agents; Binding, Competitive; Biocatalysis; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Molecular Structure; Pyrazoles; Structure-Activity Relationship; Topoisomerase Inhibitors | 2016 |
Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
Topics: Adenosine Triphosphate; Antigens, Neoplasm; Antineoplastic Agents; Binding Sites; Biocatalysis; DNA Damage; DNA Topoisomerases, Type II; DNA-Binding Proteins; Humans; Topoisomerase II Inhibitors; Xanthones | 2016 |
Novel 2-aryl-4-(4'-hydroxyphenyl)-5H-indeno[1,2-b]pyridines as potent DNA non-intercalative topoisomerase catalytic inhibitors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Humans; Molecular Docking Simulation; Pyridines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2017 |
Fluorescein hydrazones: A series of novel non-intercalative topoisomerase IIα catalytic inhibitors induce G1 arrest and apoptosis in breast and colon cancer cells.
Topics: Animals; Antigens, Neoplasm; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Female; Fluorescein; G1 Phase Cell Cycle Checkpoints; Humans; Hydrazones; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2017 |
Synthesis and topoisomerases inhibitory activity of heteroaromatic chalcones.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chalcones; DNA Topoisomerases; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Structure-Activity Relationship; Topoisomerase Inhibitors | 2016 |
Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor.
Topics: Antineoplastic Agents; Apoptosis; Benzofurans; Biocatalysis; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Design; Humans; Pyridines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2017 |
6-OH-Phenanthroquinolizidine Alkaloid and Its Derivatives Exert Potent Anticancer Activity by Delaying S Phase Progression.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Neoplasms; Phenanthrolines; Quinolizines; S Phase | 2017 |
Dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines: Topoisomerase I and IIα dual inhibitors with DNA non-intercalative catalytic activity.
Topics: Antineoplastic Agents; Biphenyl Compounds; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Halogenation; Humans; Neoplasms; Pyridines; Topoisomerase II Inhibitors | 2017 |
2-Chlorophenyl-substituted benzofuro[3,2-b]pyridines with enhanced topoisomerase inhibitory activity: The role of the chlorine substituent.
Topics: Antineoplastic Agents; Benzofurans; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Halogenation; Humans; Neoplasms; Pyridines; Topoisomerase Inhibitors | 2017 |
Design, synthesis, and biological evaluation of 1,3-diarylisoquinolines as novel topoisomerase I catalytic inhibitors.
Topics: Antineoplastic Agents; Biocatalysis; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Molecular Structure; Polymerization; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tubulin | 2018 |
Design, synthesis, and structure-activity relationships of new benzofuro[3,2-b]pyridin-7-ols as DNA topoisomerase II inhibitors.
Topics: Antineoplastic Agents; Benzofurans; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Drug Design; Drug Screening Assays, Antitumor; Etoposide; Humans; Molecular Structure; Pyridines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2018 |
Synthesis and SAR study of new hydroxy and chloro-substituted 2,4-diphenyl 5H-chromeno[4,3-b]pyridines as selective topoisomerase IIα-targeting anticancer agents.
Topics: Antineoplastic Agents; Benzopyrans; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type II; HeLa Cells; Humans; Protein Binding; Pyridines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2018 |
A new phenolic series of indenopyridinone as topoisomerase inhibitors: Design, synthesis, and structure-activity relationships.
Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Indenes; Molecular Structure; Phenols; Pyridones; Structure-Activity Relationship; Topoisomerase Inhibitors | 2018 |
Discovery and Biological Evaluations of Halogenated 2,4-Diphenyl Indeno[1,2-
Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Breast Neoplasms; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; Humans; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred ICR; Microwaves; Molecular Structure; Pyridines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2019 |
Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Halogens; Humans; Indenes; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Poly-ADP-Ribose Binding Proteins; Pyridones; Structure-Activity Relationship; Topoisomerase Inhibitors; Tumor Cells, Cultured | 2022 |